Pharmaceutical Department Residency Programs

Frequently Asked Questions

 
  1. Yes, all applicants are required to use the PhORCAS system to apply for their desired program.

  2. Yes, resident applicants are required to have completed a PGY1 residency prior to enrollment in any PGY2 experience as per ASHP-accreditation standards.

  3. Please contact the Tennessee Board of Pharmacy, or access its website for additional information and requirements for the State of Tennessee. Information about reciprocating licenses can be found at the National Boards of Pharmacy website.

  4. Residents will be expected to cover one major holiday (Christmas, Thanksgiving or New Year’s Day) or two minor holidays (Memorial Day and Labor Day). The specific holiday will be determined among the residents within one month of starting the program.

  5. Residents are provided their own office space, and general office supplies are also readily available for the residents’ use. Each resident is assigned a personal laptop computer to be used for the full academic year. Several reference texts during orientation will also be provided. Residents are given a professional development fund to be used for additional materials, memberships or additional items of the resident’s choice.

  6. Oncology - Pediatrics PGY2 residents

    Residents will be introduced to the department during July.  During the residency year, residents will be trained in operational processes with the department, including sterile products and chemotherapy preparation. Clinical coverage of weekends will be approximately every fourth weekend.

    Clinical Pharmacogenomics residents

    Residents will be introduced to the department during July.  The resident will be responsible for training in the Central Pharmacy one night a week, every other week during the first few months of the residency. Clinical coverage of weekends will be approximately every fourth weekend.

    Medication-Use Safety and Policy residents

    Residents will be introduced to the department during July.  The resident will be responsible for training in the Central Pharmacy one night a week, every week, for the first six months of the residency.  Further time will be determined with the residency program director. Clinical coverage of weekends will be approximately every fourth weekend.

  7. The St. Jude Pharmaceutical Department accepts pharmacy students from the University of Tennessee College of Pharmacy and across the country for Advanced Pharmacy Practice Experiences. Residents are expected to assist in precepting students should their rotations overlap. Residents are also expected to lead group discussions and facilitate learning experiences for PharmD students.

  8. Residents are required to attend the ASHP Midyear Clinical Meeting in December. In addition, residents are required to present their research at a regional pharmacy conference.  Residents may have the opportunity to present at a national pharmacology, oncology specialty or pharmacogenomics meeting, such as ACCP, ASCPT, HOPSA, PPAG, or the PRGN conference. Additional meetings and an optional residency class trip may be available. Funding for these opportunities vary year to year.

  9. A background in biological sciences and basic human genetics is recommended but not required. The resident, through the help of key preceptors, will be expected to become proficient in all relevant topics in genetics that will be necessary to practice in the field of clinical pharmacogenomics.

  10. Examples of recent publications from St. Jude Pharmaceutical Department Residents

    Daniels CC, Burlison JD, Baker DK, Robertson J, Sablauer A, Flynn PM, Campbell PK, Hoffman JM. Optimizing drug-drug interaction alerts using a multidimensional approach. Pediatrics. Mar 2019; 143(3): e20174111.

    Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson HD, Wolf J, Greene WL.  Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.  Antimicrob Agents Chemother. Jul 27;62(8), 2018. PMID: 29866879

    Burlison JD, McDaniel RB, Baker DK, Hasan M, Robertson JJ, Howard SC, Hoffman JM. Using EHR data to detect prescribing errors in rapidly discontinued medication orders. Appl Clin Inform. Jan;9(1):82-8, 2018. PMID 29388181

    Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur A, Relling MV, Haidar CE. An analysis of the impact of the UGT1A1 *60 allele on bilirubin serum concentrations. Pharmacogenomics Jan;18(1):5-16, 2017. PMID: 27967321

    Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nehprol Sep;32(9):1575-84, 2017. PMID: 28573537

    Watts CS, Sciasci JN, Pauley JL, Panetta JC, Pei D, Cheng C, Christensen CM, Mikkelsen TS, Pui CH, Jeha S, Relling MV. Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. J Pediatr Hemaol Oncol Aug; 38(6):449-52, 2016. PMID: 28715509

    Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins JS. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics Jul;138(1), 2016. PMID: 27335380

    McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson J, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. J Am Med Inform Assoc Apr;23(e1):e138-41, 2016. PMID: 26499101

    Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel S, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther Apr;99(4):363-9, 2016. PMID: 26417955

    Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five United States Medical Centers. Annu Rev Pharmacol Toxicol 55:89-106, 2015. PMID: 25292429

    Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc Feb;21(e1):e93-9, 2014. PMID: 23978487

    Call RJ, Burlison JD, Robertson JJ, Scott JR, Baker DK, Rossi MG, Howard SC, Hoffman JM. Adverse Drug Event Detection in Pediatric Oncology and Hematology Patients: Using Medication Triggers to Identify Patient Harm in a Specialized Pediatric Patient Population. J Pediatr Sep 165(3):447-52, 2014. PMID: 24768254

    Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, Molinelli AR, Greene WL. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother Jul-Aug;47(7-8):976-83, 2013. PMID: 23737511

    Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C, Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV. A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clin Pharmacol Ther Nov 92(5):563-6, 2012. PMID: 22990750

    Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer Sep 1;118(17):4321-30, 2012. PMID: 22252903